OT3-01-07: The BEACON Study (BrEAst Cancer Outcomes with NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (MBC) Previously Treated with an Anthracycline, a Taxane, and Capecitabine (ATC).

Multicenter Study ◽

Metastatic Breast ◽

Open Label ◽

Phase 3 ◽

Breast Cancer Outcomes ◽

Previously Treated ◽

Locally Recurrent ◽

102P Phase 3 Study Of Nktr-102 Versus Treatment of Physician's Choice (Tpc) in Patients (Pts) with Locally Recurrent or Metastatic Breast Cancer (Mbc) Previously Treated with an Anthracycline, a Taxane, and Capecitabine (Atc)

Annals of Oncology ◽

10.1016/s0923-7534(19)65753-4 ◽

2012 ◽

Vol 23 ◽

pp. ii43-ii44

Author(s):

J. Cortes ◽

E. Perez

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 3 ◽

Previously Treated ◽

Locally Recurrent ◽

Abstract S6-6: A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes

10.1158/0008-5472.sabcs12-s6-6 ◽

2012 ◽

Cited By ~ 24

Author(s):

PA Kaufman ◽

A Awada ◽

C Twelves ◽

L Yelle ◽

EA Perez ◽

...

Keyword(s):

Breast Cancer ◽

Multicenter Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Open Label ◽

Eribulin Mesylate ◽

Previously Treated

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

Yearbook of Medicine ◽

10.1016/s0084-3873(11)00184-2 ◽

2011 ◽

Vol 2011 ◽

pp. 117-118

Author(s):

J.T. Thigpen

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Open Label ◽

Phase 3 ◽

Randomised Study ◽

Abstract P6-14-18: Updated Survival Analysis of a Phase III Study (EMBRACE) of Eribulin Mesylate Versus Treatment of Physician's Choice in Subjects with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline and a Taxane

10.1158/0008-5472.sabcs10-p6-14-18 ◽

2010 ◽

Cited By ~ 5

Author(s):

C Twelves ◽

D Loesch ◽

J Blum ◽

L Vahdat ◽

K Petrakova ◽

...

Keyword(s):

Breast Cancer ◽

Survival Analysis ◽

Metastatic Breast ◽

Phase Iii ◽

Eribulin Mesylate ◽

Phase Iii Study ◽

Previously Treated ◽

Locally Recurrent ◽

Abstract S5-05: Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study

10.1158/1538-7445.sabcs15-s5-05 ◽

2016 ◽

Cited By ~ 8

Author(s):

H Wildiers ◽

S-B Kim ◽

A Gonzalez-Martin ◽

PM LoRusso ◽

J-M Ferrero ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase 3 ◽

Previously Treated ◽

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

Yearbook of Oncology ◽

10.1016/j.yonc.2011.08.015 ◽

2011 ◽

Vol 2011 ◽

pp. 34-35

Author(s):

J.T. Thigpen

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Open Label ◽

Phase 3 ◽

Randomised Study ◽

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70439-5 ◽

2014 ◽

Vol 15 (11) ◽

pp. 1269-1278 ◽

Cited By ~ 82

Author(s):

Gunter von Minckwitz ◽

Fabio Puglisi ◽

Javier Cortes ◽

Eduard Vrdoljak ◽

Norbert Marschner ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Locally Recurrent ◽

First Line Treatment

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

The Lancet ◽

10.1016/s0140-6736(11)60070-6 ◽

2011 ◽

Vol 377 (9769) ◽

pp. 914-923 ◽

Cited By ~ 614

Author(s):

Javier Cortes ◽

Joyce O'Shaughnessy ◽

David Loesch ◽

Joanne L Blum ◽

Linda T Vahdat ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Open Label ◽

Phase 3 ◽

Randomised Study ◽

Faculty Opinions recommendation of Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.9304956.9915055 ◽

2011 ◽

Author(s):

Jeffrey Peppercorn ◽

Blair Irwin

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Open Label ◽

Phase 3 ◽

Randomised Study ◽

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30313-3 ◽

2017 ◽

Vol 18 (6) ◽

pp. 743-754 ◽

Cited By ~ 144

Author(s):

Ian E Krop ◽

Sung-Bae Kim ◽

Antonio Gonzalez Martin ◽

Patricia M LoRusso ◽

Jean-Marc Ferrero ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Previously Treated ◽